bioRxivCancer BiologyPreprint
Repeat element-anchored enhancer-promoter interactions (REEPIs) shape the regulatory landscape of hormone-resistant breast cancer
Xufeng ShuiD, Shengliang NiiD, Mitsuyoshi MurataiD, Maierdan PalihatiiD, Hisashi MiuraiD, Ichiro HirataniiD, Chi Wai YipiD, Hazuki TakahashiiD, Takeya KasukawaiD, Noriko SaitohiD, Masaki KatoiD, Piero CarninciiD
Abstract
Repeat elements (REs) comprise over half of the human genome and are increasingly recognized as regulatory components, yet their role in therapy resistance remains unclear. Here, we integrate CAGE and RADICL-seq to map regulatory elements and RNA-chromatin interactions in estrogen receptor-positive breast cancer cells (MCF7) and their long-term estrogen-deprived (LTED) derivatives. We identify repeat element-anchored enhancer-promoter interactions (REEPIs), defined by the presence of annotated REs at both enhancer and promoter sites. In LTED cells, REEPIs are enriched for ERV1 and ERVL elements and involve specific repeat pairings associated with transcription factor combinations such as SP1-SMAD3 and SP1-NFYC. At the gene level, these REEPIs are preferentially linked to genes involved in chromatin remodeling, DNA repair, and lineage plasticity. Our findings reveal a repeat-guided regulatory architecture associated with transcriptional adaptation in endocrine resistance and identify REEPIs as a previously underexplored component of regulatory reprogramming in hormone-resistant breast cancer.
- organism: human
- assay: ChIP-seq
- assay: Hi-C
- research focus: chromatin & epigenetic regulation
- research focus: cell type annotation
- research focus: gene regulatory network inference
- approach: deep learning
- approach: statistical model
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Genetic and epigenetic driven variation in regulatory regions activitycontribute to adaptation and evolution under endocrine treatment
N. Slaven, R. Lopes, … L. Magnani·bioRxiv·Feb 15, 2022
- ER-positive breast cancer cells are poised for RET-mediated endocrine resistance
S. Horibata, E. J. Rice, … C. G. Danko·bioRxiv·Sep 21, 2017
- Endocrine therapy-specific lineage and partial epithelial-mesenchymal reprogramming defines divergent resistant cell-states in ER+ breast cancer
Sarthak Sahoo, Sejal Khanna, … Mohit Kumar Jolly·bioRxiv·May 13, 2026
- Epigenetic therapy targets the 3D epigenome in endocrine-resistant breast cancer
Joanna Achinger-Kawecka, Clare Stirzaker, … Susan J. Clark·Nature Structural & Molecular BiologyPeer-reviewed·Jan 5, 2024
- Coordinate Enhancer Reprogramming by GATA3 and AP1 Promotes Phenotypic Plasticity to Achieve Breast Cancer Endocrine Resistance
- Promoter-centric gene regulation in drug-resistant cancer
Vasumathi Kameswaran, Sayantanee Paul, … Bence Dániel·bioRxiv·Feb 20, 2025